Linvoseltamab
Phase 2Active 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Smoldering Multiple Myeloma (SMM)
Conditions
Smoldering Multiple Myeloma (SMM)
Trial Timeline
Jan 30, 2024 → Jan 25, 2033
NCT ID
NCT05955508About Linvoseltamab
Linvoseltamab is a phase 2 stage product being developed by Regeneron Pharmaceuticals for Smoldering Multiple Myeloma (SMM). The current trial status is active. This product is registered under clinical trial identifier NCT05955508. Target conditions include Smoldering Multiple Myeloma (SMM).
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (7)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07181941 | Phase 1/2 | Recruiting |
| NCT06140524 | Phase 2 | Recruiting |
| NCT06376526 | Phase 2 | Recruiting |
| NCT06292780 | Phase 1/2 | Recruiting |
| NCT05955508 | Phase 2 | Active |
| NCT05828511 | Phase 1/2 | Recruiting |
| NCT03761108 | Phase 1/2 | Recruiting |
Competing Products
13 competing products in Smoldering Multiple Myeloma (SMM)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Elotuzumab (BMS-901608; HuLuc63) | AbbVie | Phase 2 | 52 |
| BHQ880 | Novartis | Phase 2 | 52 |
| carfilzomib + Lenalidomide + Dexamethasone + Melphalan | Amgen | Phase 2 | 51 |
| Denosumab | Amgen | Phase 2 | 51 |
| Carfilzomib + Lenalidomide + Daratumumab + Dexamethasone | Amgen | Phase 2 | 51 |
| Elranatamab | Pfizer | Phase 2 | 51 |
| Nivolumab + Lenalidomide + Dexamethasone | Bristol Myers Squibb | Phase 2 | 51 |
| Elotuzumab + Lenalidomide + Dexamethasone | Bristol Myers Squibb | Phase 2 | 51 |
| Dexamethasone + Iberdomide Hydrochloride | Bristol Myers Squibb | Phase 2 | 51 |
| Linvoseltamab + Daratumumab | Regeneron Pharmaceuticals | Phase 3 | 76 |
| Selinexor | Karyopharm Therapeutics | Phase 2 | 44 |
| IPH2101 | Innate Pharma | Phase 2 | 44 |
| PD-L1 peptide | IO Biotech | Phase 2 | 44 |